How to interpret clinical trial results like a pro

This field spans through most scientific disciplines, studying cell imaging, stem cells, cell physiology and structure, cell signaling, cell culture, and translational biology, and encompassing other scientific fields such as cancer biology, neuroscience, genetics, bioengineering and so much more. The free, two-day conference will bring together professors, post-docs, biologists and biomedical professionals from all over the world.

We will introduce Chromassette® and an application example of an integrated rapid single pass process from harvest to purified bulk, a concept demonstrated by AbbVie. Chromassette is a stackable, single-use and pre-packed chromatography cassette with a supported bed, addressing the current key challenges in manufacturing. Chromassette enhances the separation capabilities of chromatography resins and combines it with the convenience of a modular cassette.

As the prevalence of diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that will aid in the diagnosis and management of patients. This is a complex process that poses challenges for patients, physicians, hospitals and laboratories. What is changing in today’s world is that many hospitals are being asked to take steps toward improving proactive and preventive care, improving patient outcomes while also saving on healthcare costs associated with diabetes and diabetes complications. Laboratories are invaluable partners in addressing this challenge.

Understanding the biology of your therapeutic is key to effectively and efficiently progressing it from first principles, through safety assessment studies, and into clinical trials. The unique characteristics and specific biology of each large molecule therapeutic make it impossible to design a “one size fits all” approach to non-clinical development, requiring instead a design tailored to each molecule. For efficient development strategies, this should include a thorough understanding of the disease and therapeutic biology as well as ensuring that the most appropriate studies are conducted to progress each molecule. Despite the need for unique approaches for each novel biologic, there are seven key steps that should be considered when developing biologics through non-clinical development in order to ensure effective and efficient progress.